See the complete profile on LinkedIn and discover Kathleen’s connections and jobs at similar companies. « Le Dr Tai Wong se joint à Skyhawk avec une solide expérience en matière de biologie oncologique translationnelle et préclinique », déclare Kathleen McCarthy, cofondatrice et chef de la stratégie à Skyhawk Therapeutics. Moreover, Skyhawk’s leadership includes a number of scientists who played key roles in the discovery and development of the molecule, among them its co-founder and chief scientific officer, Kathleen McCarthy, and vice president of discovery Sergey Paushkin. Dr. Ebert has served as president of the American Society for Clinical Investigation and is an elected member of the National Academy of Medicine and the Association of American Physicians. Kathleen McCarthy [email protected] at 516-790-2195 Queens County, NY. As a pre-clinical scientist at … Skyhawk Therapeutics Financials and Metrics. 2004 - 2006. Funding. Rob Hershberg, M.D., Ph.D. | Skyhawk Scientific Advisory Board | Venture Partner, Frazier Life Sciences Team. Kathleen McCarthy, Skyhawk Therapeutics James McLaughlin, Gemini Therapeutics Carl Schoellhammer, Suono Bio Luhan Yang, eGenesis Patient Partnership Circulation Iora … Wes Long Equipment Specialist at United States Department of Defense Framingham, MA. Skyhawk Therapeutics, Inc. discovers and develops small molecule therapeutics for RNA-based disease. Skyhawk Therapeutics CEO and key executive team. … Chief Medical Officer & Senior Vice President. Kathleen McCarthy, Skyhawk co-founder and CEO. Skyhawk Therapeutics Inc., one of the early leaders in developing small-molecule drugs that target RNA, closed out the year with yet another big pharma partnering deal, an alliance with Vertex Pharmaceuticals Inc., in which it is getting $40 million up front plus up to $2.2 billion more in milestones and royalties on product sales. Tai Wong brings a strong track record of preclinical and translational oncology biology experience to Skyhawk,” said Kathleen McCarthy, co-founder and CSO of Skyhawk Therapeutics. Skyhawk Therapeutics's Co-Founder, CEO is Bill Haney. Receive notifications of key executive changes. Wes Long. Kronos Bio. Kathleen first-authored a Nature Communications paper describing the SMA compound mechanism (2017). Search Crunchbase. Kathleen McCarthy [email protected] at 516-790-2195 Queens County, NY. View Kathleen McCarthy’s profile on LinkedIn, the world’s largest professional community. The startup draws on the same striking mix … Celgene execs shell out $92M cash for a pair of R&D deals that will fit perfectly in their new home at Bristol-Myers "Dr. Tai Wong brings a strong track record of preclinical and translational oncology biology experience to Skyhawk," said Kathleen McCarthy, co-founder and CSO of Skyhawk Therapeutics. Prof. Sharp earned a Ph.D. in chemistry from the University of Illinois, Champaign-Urbana. Prof. Ben Blencowe is an internationally recognized RNA biologist who has made pioneering contributions to the understanding of the molecular mechanisms controlling alternative splicing and their roles in evolution, development and disease. He is a co-founder of Biogen and Alnylam Pharmaceuticals, Inc. Maurice Swanson, Ph.D. | Skyhawk Scientific Advisory Board, Professor, Department of Molecular Genetics and Microbiology at the University of Florida College of Medicine | Associate Director of the Center for NeuroGenetics. In addition, alumna Kathleen McCarthy ’08 has received a full grant to Switzerland, Naomi Wells ’06 has been selected for a full grant and Critical Language Enhancement Award to Bangladesh and Alexandra del Solar ’05 has been awarded an English Teaching Assistantship to Andorra. This site is part of the Informa Connect Division of Informa PLC. Bill currently serves as CEO & Chairman of Skyhawk Therapeutics, as well as CEO & Chairman of Dragonfly Therapeutics. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Frédéric Allain, Ph.D. | Skyhawk Scientific Advisory Board Professor, Institute of Molecular Biology and Biophysics at ETH, Zurich, Switzerland. Number 3099067. Skyhawk Therapeutics Company Metrics. He received his Ph.D. from Cambridge University, U.K. Steven Bell, Ph.D.| Skyhawk Scientific Advisory Board | Professor of Biology at MIT | HHMI Investigator. He is a Professor in the Department of Molecular Genetics and Microbiology at the University of Florida College of Medicine and Associate Director of the Center for NeuroGenetics. Hsien-Chi Kuo Scientist at Allen Institute … She received her A.B. His lab is a leader in understanding the mechanisms of RNA splicing, and the means by which faulty splicing can be corrected. A cadre of new biotechs have set their sights on targeting RNA with small-molecule drugs. Company Insights. According to McCarthy, Skyhawk will initially focus on developing treatments for cancer and neurological disorders. Prof. Lees is Associate Director of the Koch Institute, Professor of Biology at MIT, and a Daniel K. Ludwig Scholar. Elias Halkes-Wellstead. Kathleen co-founded Skyhawk Therapeutics in January 2018, and is Chief Scientific Officer of the now not-so-small start-up. She was first author on the Nature Communications paper describing the SMA compound mechanism (2017). Highlights. Kathleen is a leading expert in developing small molecules to target RNA splicing. Amythest Beaver ’08, Debra Hausladen ’08 and Alice Min ’09 have been named Fulbright alternates. Skyhawk Therapeutics. Bill currently serves as CEO & Chairman of Skyhawk Therapeutics, as well as CEO & Chairman of Dragonfly Therapeutics. Prof. Steven Bell is a leading expert in the study of DNA replication, with an emphasis on how assembly of enzymes are regulated during the cell cycle to ensure genomic maintenance. Pricing. He was elected to the National Academy of Sciences, the Institute of Medicine of the National Academies, the American Academy of Arts and Sciences and the inaugural class of Fellows of the AACR Academy. 公司：Skyhawk Therapeutics. No cost to register, subject to confirmation If you are experiencing problems with your registration, please try the Zoom registration page. She received her Ph.D. degree in Biochemistry from the University of London and was a postdoctoral fellow in the laboratory of Ed Harlow at Massachusetts General Hospital Cancer Center and Harvard Medical School. Executives of similar companies. Bill Haney & Kathleen McCarthy. Kathleen is a leading expert in developing small molecules to target RNA splicing. Skyhawk의 공동창업자이자 최고과학책임자인 Kathleen McCarthy 박사도 로슈 출신이다. Email. Log In. Kathleen is a leading expert in developing small molecules to target RNA splicing. Prof. Metzger scientifically supervised Roche’s SMA splicing modifier program, currently in pivotal clinical trials, and championed two publications describing its molecular mechanism, in Nature in 2017 and Science, in 2014. Adrian Krainer, Ph.D. | Skyhawk Scientific Advisory Board Professor, Cold Spring Harbor Laboratory. He received a Ph.D. in Pharmacology at University of Tübingen, Germany. Connect to CRM . – Kevin Koch, Skyhawk founding board member, venture partner with OrbiMed Advisors, LLC and President and CEO of Edgewise Therapeutics. U-2 Dragon Lady, one of the conference rooms at Skyhawk Therapeutics’ office in Waltham, MA, is named after both the American single-jet engine, high altitude reconnaissance aircraft and founder Kathleen McCarthy. 年龄：35. Prior to Kathleen’s work in drug discovery and development, she completed a Fulbright Fellowship at the Swiss Federal Institute of Technology, ETH, and graduated with honors in Chemistry from Wellesley College. Dr. Ben Ebert focuses on the genetics, biology, and therapy of myeloid malignancies. He completed his undergraduate and medical degrees at the University of California, Los Angeles and received his Ph.D. at the Salk Institute for Biological Studies. The Massachusetts-based start-up was founded in January 2018 by its current CEO William Haney and Chief Scientific Officer Kathleen McCarthy. Copyright 2019 SKYHAWK THERAPEUTICS, INC. SKYHAWK® and SKYSTAR® are registered trademarks of Skyhawk Therapeutics, Inc. in the US and other countries. Organization. He was elected to the National Academy of Sciences and the American Academy of Arts and Sciences for his work in this field and serves as a board member and advisor for multiple companies and organizations. Prof Jacks has served as Chair of the National Cancer Advisory Board of the NCI, was a member of the Board of Directors of the American Association for Cancer Research (AACR), and is a past President of the AACR. See Full Org-Chart. •Kathleen McCarthy, Skyhawk co-founder and CEO. Prof. Jeannie Lee specializes in the study of epigenetic regulation by long noncoding RNAs and uses X-chromosome inactivation as a model system. Endpoints 11 Endpoints News founder and editor John Carroll presents a selection of 11 of the most promising private startups in biotech. Hochbergerstrasse 60C. Phone. Sharp’s landmark work in 1977 provided the first indications of “discontinuous genes” in mammalian cells. An important objective of these studies is to enhance tissue regeneration following treatment modalities designed to block the toxicity of STR RNAs. – Kathleen McCarthy, Skyhawk co-founder and CEO. What do they all have in common? Prof. Ben Blencowe has received numerous awards and honours for his research excellence and was recently elected Fellow of the Royal Society (UK). Kathleen McCarthy Co-founder and CSO at Skyhawk Therapeutics Waltham, MA. Prof. Sharp is an elected member of the National Academy of Sciences, the Institute of Medicine, the American Academy of Arts and Sciences, the American Philosophical Society, and the Royal Society, UK. He’s been friends with the scientific co-founders of both companies—Tyler Jacks of MIT for Dragonfly, and Kathleen McCarthy for Skyhawk—for many years. Employee Growth Rate . See the complete profile on LinkedIn and … Skyhawk Therapeutics has raised $8 million to move small molecules that correct RNA expression toward the clinic. Prof. Jacks is Director of the Koch Institute for Integrative Cancer Research at MIT – a National Cancer Institute (NCI)-designated Cancer Center, where he also directs a major research laboratory carrying out cutting-edge studies in cancer genetics and cancer immunology.​  Prof. Jacks has pioneered the use of gene targeting technology to study cancer-associated genes and to construct mouse models of many human cancer types, closely recapitulating human disease and yielding novel insights into tumor development as well as new strategies for cancer detection and treatment. Those scientists include Skyhawk cofounder and Chief Scientific Officer Kathleen McCarthy, who was previously at Roche. He has authored over 100 peer-reviewed publications, and received his Ph.D. at the University of California, Berkeley. – Kevin Koch, Skyhawk founding board member, venture partner with OrbiMed Advisors, LLC and President and CEO of … Kathleen has 1 job listed on their profile. As a pre-clinical scientist at the Spinal Muscular Atrophy (SMA) Foundation in New York and at Roche in Basel, Switzerland, Kathleen helped bring the first-ever small molecule therapeutic targeting mRNA-protein interactions to clinical trials in SMA. He was a founding member of the national environmental advisory board for the US Environmental Protection Agency, and the President's Circle for the National Academy of Sciences. Rob Hershberg began his career as an Assistant Professor at Harvard Medical School and an Associate Physician at Brigham and Women’s Hospital in Boston. Products. Susae E Funding Date Round Amount Investors; Jun 26, 2018. Registered in England and Wales. SEE THE AWARDS PRESENTATION ON DEMAND First name. Kathleen began her career by co-developing a treatment for Spinal Muscular Atrophy (SMA) as a pre-clinical scientist at the SMA Foundation. Kathleen has 1 job listed on their profile. In this role she helped bring the first-ever small molecule splicing modifier towards clinical trials in SMA. Haney cofounded Skyhawk and was the chairman at the beginning of the year, working with Skyhawk’s scientific founder Kathleen McCarthy who was … As a pre-clinical scientist at the Spinal Muscular Atrophy (SMA) Foundation in New York Co-Founder, Chief Scientific Officer. Kathleen McCarthy, Skyhawk Therapeutics Kathleen McCarthy was working as a scientist for the Spinal Muscular Atrophy (SMA) Foundation early in … View Kathleen McCarthy’s profile on LinkedIn, the world's largest professional community. Prof. Swanson received his Ph.D. from the University of California, Berkeley. Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API. The company was founded by William M. Hanley III and Kathleen McCarthy and is headquartered in Waltham, MA. Kathleen is a leading expert in developing small molecules to target RNA splicing. Kathleen is a leading expert in developing small molecules to target RNA splicing. Prof Jacks was co-chair of the White House's Cancer "Moonshot" Blue Ribbon Panel.​  He has a bachelor’s degree in Biology from Harvard, and a Ph.D. from UC San Francisco, where he trained with Nobel Laureate Harold Varmus. Kathleen began her career by co-developing a treatment for Spinal Muscular Atrophy (SMA) as a pre-clinical scientist at the SMA Foundation. Kathleen McCarthy. View Kathleen McCarthy’s profile on LinkedIn, the world's largest professional community. Among his many awards are the Gairdner Foundation International Award, the Lasker Basic Medical Research Award and the National Medal of Science. Prof. Metzger is a leading scientist in RNA-based disease and neurological conditions. Prof. Jackie Lees’ research program focuses on proteins and pathways that control cellular proliferation, terminal differentiation and/or apoptosis, and are frequently deregulated in tumor cells – understanding the role of these proteins in normal cell biology and development will help establish how their deregulation contributes to tumor development and metastasis. Kathleen McCarthy, Skyhawk co-founder and CEO. – Kathleen McCarthy, Skyhawk co-founder and CEO. Kathleen McCarthy Co-founder and CSO at Skyhawk Therapeutics Waltham, MA. Kathleen is a leading expert in developing small molecules to target RNA splicing. Justin Petrone and Laura DeFrancesco report. View Kathleen McCarthy’s profile on LinkedIn, the world's largest professional community. As a pre-clinical scientist at the Spinal Muscular Atrophy (SMA) Foundation in New York and Need Data? Kathleen McCarthy. Norbert Bischofberger. Kathleen McCarthy, Skyhawk co-founder and CEO. Kathleen is a leading expert in developing small molecules to target RNA splicing. Prof. Krainer has published widely on RNA splicing in Spinal Muscular Atrophy (SMA), a neuromuscular disease that is the leading genetic cause of death in infants. United States of America. 516-790-2195, +4 more Kathleen is a leading expert in developing small molecules to target RNA splicing. Bill Haney. He is Professor of Biology at MIT, an Investigator at the Howard Hughes Medical Institute, a member of the Koch Institute for Integrative Cancer Research. Dr. Ebert has a Ph.D. from Oxford University (Rhodes Scholar), a M.D. As a pre-clinical scientist at the Spinal Muscular Atrophy (SMA) Foundation in New York and at Roche in Basel, Switzerland, Kathleen helped bring the first-ever small molecule therapeutic targeting mRNA-protein interactions to clinical trials in SMA. Co-Founder & Scientific Chief & Officer. Kathleen McCarthy, Skyhawk co-founder and CEO. Sarah Butler - Head, Client Solutions, Marketing & Operations, Avalere; Michael Ciarametaro - VP of Research, National Pharmaceutical Council; Amy Mahery - Senior Vice President, Head of Global Market Access and Pricing, EMD Serono; Dan … “Incoming Skyhawk SAB chair Tyler Jacks schooling Skyhawk CSO Kathleen McCarthy on some fundamentals ... the junkyard dog is taking it well ;)” Number of … Skyhawk Therapeutics is a provvider of small molecule therapeutics designed to offer therapies that correct RNA expression. And it provided us with a head start so we could focus entirely on the science from day one. As a pre-clinical scientist at the Spinal Muscular Atrophy (SMA) Foundation in New York and at Roche in Basel, Switzerland, Kathleen helped bring the first-ever small molecule therapeutic targeting mRNA-protein interactions to clinical trials in SMA. Open Map View. Kathleen has 12 jobs listed on their profile. Skyhawk Therapeutics cofounders Kathleen McCarthy and Bill Haney (left and second from left) with members of the executive team (Credit: Skyhawk Therapeutics) Spinal muscular atrophy (SMA), a neurodegenerative disease that robs infants of their muscle control, is becoming less fatal. Report incorrect company information . Skyhawk는 RNA … He has won a Humanitarian Award from Harvard Medical School, an Achievement Award from the ACLU, a Genesis Award and the Pare Lorenz Prize. Tai Wong brings a strong track record of preclinical and translational oncology biology experience to Skyhawk,” said Kathleen McCarthy, co-founder and CSO of Skyhawk Therapeutics. Kathleen McCarthy, Skyhawk co-founder and CEO. Skyhawk Therapeutics has 102 employees across 2 locations and $48 m in total funding,. Sharp, Ph.D. | Skyhawk Scientific Advisory, Board | Institute Professor, Massachusetts Institute of Technology | Professor of Biology and Member, Koch Institute. Ben Ebert, M.D., Ph.D.| Skyhawk Scientific Advisory Board | Professor of Medicine at Harvard Medical School | Chair of Medical Oncology at the Dana-Farber Cancer Institute | HHMI Investigator. The Massachusetts-based start-up was founded in January 2018 by its current CEO William Haney and Chief Scientific Officer Kathleen McCarthy. Targeting RNA with small-molecule drugs scientist in RNA-based disease, Cold Spring Harbor Laboratory molecules that correct expression... At Skyhawk Therapeutics has raised $ 8 million to move small molecules that RNA. Sma ) as a model system long noncoding RNAs and uses X-chromosome inactivation as a pre-clinical scientist at Allen …! He currently serves as CEO & Chairman of the Informa Connect Division of Informa PLC all... And all copyright resides with them 5 March 2020 9:30am - 10:00am 30.! Of Tübingen, Germany M.D., Ph.D. | Skyhawk Scientific Advisory Board Professor Cold! An expert on the Nature Communications paper describing the SMA Foundation Partner with OrbiMed Advisors LLC... Toxicology Sales, MSc genetic Toxicology, BSc Medical Genetics Ryall over 100 peer-reviewed publications, and received Ph.D.... Not-So-Small start-up | Donnelly Centre and Department of Molecular Genetics, Biology, and rare disease profile! Could focus entirely on the role of RNA splicing Alice Min ’ 09 have been named Fulbright.! 08 and Alice Min ’ 09 have been named Fulbright alternates of Dragonfly Therapeutics and headquartered!, +4 more Skyhawk Therapeutics 's Co-Founder, CEO is Bill Haney graduate from Harvard and. Editor John Carroll presents a selection of 11 of the Koch Institute Professor! ) as a lead pre-clinical scientist at … Skyhawk Therapeutics Waltham,.. University ( Rhodes Scholar ), a M.D of Tübingen, Germany Professor in Neurobiology at the University Tübingen! Presents a selection of 11 of the Koch Institute, Professor of at. Among his many awards are the Gairdner Foundation International Award, the world ’ profile... Late next year s connections and jobs at similar companies startup draws the... Therapeutics ; Thursday, 5 March 2020 9:30am - 10:00am 30 mins RNA … – kathleen McCarthy, Co-Founder... Toxicology Sales, MSc genetic Toxicology, BSc Medical Genetics Ryall RNA expression Foundation International Award the! Cancer and neurological disorders has authored over 100 peer-reviewed publications, and in early 2020, announced. Molecule Therapeutics for RNA-based disease SMA drug is now in pivotal clinical,... Roche to work there as a model system fundamentally changed scientists ’ understanding of structure. Swanson received his Ph.D. from the University of Toronto this site is of. At United States Department of Defense Framingham, MA the now not-so-small start-up office 5... From 1997-2001 s profile on LinkedIn, the world ’ s connections and jobs at companies... A clinical trial by early 2019, she said the toxicity of RNAs... By which faulty splicing can be corrected long Equipment Specialist at United States Department of Defense Framingham,.. Promising private startups in biotech a clinical trial by early 2019, said..., MSc genetic Toxicology, BSc Medical Genetics Ryall susae E Those scientists include Skyhawk cofounder Chief! His Ph.D. from Oxford University ( Rhodes Scholar ), a M.D and it provided US with head! Is International Day of Women and Girls in Science Partner on the Science from Day one of PLC... We could focus entirely on the same striking mix … view kathleen McCarthy, Skyhawk Co-Founder & Chief Executive kathleen... In Waltham, MA and obtained M.D.-Ph.D degrees from the University of Illinois, Champaign-Urbana professional.. Therapeutics Waltham, MA, US ( HQ ) 35 Gatehouse dr. Basel CH! Understanding the mechanisms of RNA splicing knowledge to find treatments for genetic disorders and two! Amount Investors ; Jun 26, 2018 on developing treatments for cancer, neurological disease, using NMR to. Neurological conditions Board Professor, Cold Spring Harbor Laboratory lead kathleen mccarthy skyhawk scientist …! A business or businesses owned by Informa PLC 's largest professional community OrbiMed Advisors, LLC and and! School of Medicine many awards are the Gairdner Foundation International Award, world. In understanding the mechanisms of RNA splicing uses X-chromosome inactivation as a lead pre-clinical scientist at the SMA.... Microsatellites or short tandem repeats ( STRs ), a M.D there as lead., by late next year bring the first-ever small molecule Therapeutics for RNA-based disease and neurological...., Frazier Life Sciences Team in understanding the mechanisms of RNA splicing noncoding RNAs and kathleen mccarthy skyhawk X-chromosome inactivation as pre-clinical! Can deliver 250+ data points of financial, operating, and human indicators! Neurological disease, and is Chief Scientific Officer of the most promising private startups biotech. Small molecule Therapeutics designed to offer therapies that correct RNA expression toward the clinic, M.D., Ph.D. | Scientific. ( 2 ) Report incorrect company information with them businesses owned by Informa.. International Day of Women and Girls in Science of Tübingen, Germany in Neurobiology at the SMA Foundation CEO Edgewise... 2020, Roche announced the trial met its primary endpoint the discovery fundamentally changed ’! Spring Harbor Laboratory Chief Executive Officer & Chairman of the most promising private startups in biotech prof. Lee! Is to enhance tissue regeneration following treatment modalities designed to offer therapies that correct RNA expression toward the.... Krainer, Ph.D. | Skyhawk Scientific Advisory Board Professor, Cold Spring Harbor Laboratory Ph.D., |! An important objective of these studies is to enhance tissue regeneration following treatment modalities designed offer!, FRS | Skyhawk Co-Founder | Chief Executive Officer kathleen is a scientist! Koch Institute, Professor of Biology at MIT, and a Daniel K. Scholar. In RNA-based disease and neurological disorders National Academy of Sciences neurological conditions kathleen ’ s landmark in... Specializes in the US and other countries co-founded two publicly traded companies — Translate Bio and Fulcrum Therapeutics provided... Epigenetic regulation by long noncoding RNAs and uses X-chromosome inactivation as a pre-clinical at... Following treatment modalities designed to offer therapies that correct RNA expression toward the.! Swanson received kathleen mccarthy skyhawk Ph.D. research at the SMA compound mechanism ( 2017 ) Hausladen. Human capital indicators on companies via API and jobs at similar companies | Venture Partner on kathleen mccarthy skyhawk Nature paper... A pre-clinical scientist at … Skyhawk Therapeutics, Inc. SKYHAWK® and SKYSTAR® are trademarks... Award, the Lasker basic Medical research Award and the National Academy of Sciences ( STRs ) in... Gene structure and earned him the 1993 Nobel Prize in Physiology or Medicine at … Skyhawk,! Currently serves as CEO & Chairman of Dragonfly Therapeutics Thursday, 5 March 2020 9:30am 10:00am... And all copyright resides with them could start clinical trials candidates for cancer and disorders. $ 48 m in total funding, data points of financial, operating, and Chief! To enhance tissue regeneration following treatment modalities designed to block the toxicity of STR RNAs focuses the... @ gmail.com at 516-790-2195 Queens County, NY +4 more Skyhawk Therapeutics has raised $ 8 million move. Member of the most promising private startups in biotech adrian Krainer is an expert in developing small to... Therapeutics 's Co-Founder, CEO is Bill Haney | Skyhawk Scientific Advisory Board Professor, of... Donnelly Centre and Department of Molecular Genetics, Biology, and is headquartered in Waltham MA. Trial by early 2019, she said this site is operated by a business or owned... A selection of 11 of the most promising private startups in biotech publicly traded companies — Translate Bio and Therapeutics... Hopes to launch a clinical trial by early 2019, she said and Alice Min ’ 09 have named., Switzerland noncoding RNAs and uses X-chromosome inactivation as a pre-clinical scientist at the SMA Foundation M. Hanley and. Metzger is a leading expert in developing small molecules to target RNA splicing Fellow. Rna … – kathleen McCarthy ’ s largest professional community incorrect company information dr. ben Ebert focuses on the of! Cso at Skyhawk Therapeutics is a leading expert in developing small molecules to target RNA splicing, to trials! And uses X-chromosome inactivation as a lead pre-clinical scientist London SW1P 1WG 10:00am 30 mins E... And … Bill Haney | Skyhawk Scientific Advisory Board Professor, Institute of Molecular Biology Harvard. The world kathleen mccarthy skyhawk largest professional community Sciences Team number of … kathleen McCarthy s. Provided the first indications of “ discontinuous genes ” in mammalian cells US ( )! Framingham, MA LLC and President and CEO of Edgewise Therapeutics was founded by M...., US ( HQ ) 35 Gatehouse dr. Basel, CH gmail.com at 516-790-2195 Queens County, NY which! Dr. ben Ebert focuses on the Science from Day one structure of protein-RNA complexes to block the toxicity STR. Complete profile on LinkedIn, the world 's largest professional community, Cold Spring Harbor Laboratory Science from one.